After interim analysis CureVac defends its vaccine

Status: 06/18/2021 10:19 a.m.

Although an interim analysis of the CureVac vaccine only showed an effectiveness of 47 percent, company boss Haas does not want to know anything about a failure. He is hoping for further tests so that the vaccine will be ready for the market after all. The negative news for the Tübingen company CureVac continues. At first, the company lagged behind the competition in developing its corona vaccine. Then the company went late to the crucial phase 3 to test its vaccine – at that time there were already several variants of the coronavirus. The next bad news followed yesterday: CureVac announced in a mandatory stock market announcement that, according to an interim analysis, its corona vaccine had a preliminary effectiveness of 47 percent against Covid 19 disease “of any severity” have. The value is significantly higher for the other preparations approved in the EU.

06/17/2021

CureVac Story of a disappointed hope

While the world is now being vaccinated with BioNTech, CureVac has proven to be ineffective. Why?

“Wild type hardly plays a role anymore”

Company boss Franz-Werner Haas has now gone on the offensive. He defended the company’s corona vaccine against the dpa news agency. No other vaccine has been tested on so many virus variants, he said.

“In fact, it is actually not correct to compare the number of the provisional effectiveness of our corona vaccine and the numbers of the effectiveness of other vaccines”said Haas. The study on the corona vaccine candidate CVnCov contained 29 virus variants. The original virus, the wild type, hardly plays a role anymore. “The efficacy figures for the other vaccines would probably look different if their studies had been carried out at a later date.”

06/17/2021

CureVac vaccine not very effective Crash of a Bearer of hope

The CureVac crash hits countless private investors, taxpayers and the German vaccination campaign.

Degree in three weeks

The Tübingen-based company would like to complete the analysis of the data from the final study phase in the next two to three weeks. Haas was convinced that the effectiveness of the vaccine would change again. As soon as this has been completed, CureVac will advise the EMA as to whether further data is required.

The company remains convinced that it will bring its vaccine to approval. According to Haas, even a possibly relatively low effectiveness should not stand in the way. “In view of the pandemic, it can only be said: If there is an effective vaccine, it should also be used.” Haas also referred to the numerous developing countries in which little or no corona vaccines are currently available. The scientific director of the vaccine study at CureVac, Peter Kremsner, believes that it will certainly be possible to make the vaccine operational. In an interview with the BR he said: “That will work for sure. From my point of view, this will not be possible in the next few weeks. But it will be possible to prepare the vaccine so that it can be very effective.”

06/17/2021

Corona vaccine CVnCoV Bad Intermediate result for CureVac

CureVac’s CVnCoV vaccine showed only 47 percent effectiveness in the interim analysis.

“It was a noble cause”

The SPD health expert Karl Lauterbach estimates that the setback when entering the market will contribute to the vaccination campaign losing pace for two to three weeks. The promise of the federal government to make a vaccination offer to all adults by the end of the summer is not at risk. “We will reach herd immunity in mid-September”said Lauterbach in the daily topics .

Lauterbach pointed out that the CureVac serum is the “noble” I wanted to be a cheap and very effective vaccine. It would have been predestined for poorer countries. The EU had promised 400 million doses of CureVac to poorer countries. Lauterbach assessed it as a tragedy that this delivery has now been canceled.

No withdrawal of the investor

The announcement of the preliminary effectiveness had caused a drastic plunge in the stock exchange price of CureVac. Investor Dietmar Hopp still believes in the company. He will definitely stay as an investor, he said “Munich Mercury”. He is a firm believer in the company.

Exclusive 02/02/2021

Vaccine in short supply in Europe What about CureVac?

CureVac was seen as a leader in vaccine development, but the company has now grown quiet.

The federal government is also holding on to its stake in CureVac, as the Ministry of Economic Affairs said. Last year, he entered CureVac through the KfW development bank with 300 million euros and, according to KfW, holds a share of 16 percent. The federal government has no influence on the operational business, explained the ministry spokeswoman